scholarly journals Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?

2005 ◽  
Vol 7 (3) ◽  
Author(s):  
Stephen RD Johnston
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Oestrogen Receptor ◽  
Selective Oestrogen Receptor Modulators ◽  
Receptor Modulators

scholarly journals Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care

2019 ◽  
Vol 69 (689) ◽  
pp. e836-e842 ◽  
Author(s):  
Jennifer G McIntosh ◽  
Jesse Minshall ◽  
Sibel Saya ◽  
Adrian Bickerstaffe ◽  
Nadira Hewabandu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Oestrogen Receptor ◽  
Informed Choice ◽  
Cross Sectional ◽  
Selective Oestrogen Receptor Modulators ◽  
Reduce Breast Cancer Risk ◽  
Receptor Modulators

BackgroundIn Australia, evidence-based guidelines recommend that women consider taking selective oestrogen receptor modulators (SERMs) to reduce their risk of breast cancer. In practice, this requires effective methods for communicating the harms and benefits of taking SERMs so women can make an informed choice.AimTo evaluate how different risk presentations influence women’s decisions to consider taking SERMs.Design and settingCross-sectional, correlational study of Australian women in general practice.MethodThree risk communication formats were developed that included graphics, numbers, and text to explain the reduction in breast cancer risk and risk of side effects for women taking SERMs (raloxifene or tamoxifen). Women aged 40–74 years in two general practices were shown the risk formats using vignettes of hypothetical women at moderate or high risk of breast cancer and asked to choose ‘If this was you, would you consider taking a SERM?’ Descriptive statistics and predictors (risk format, level of risk, and type of SERM) of choosing SERMs were determined by logistic regression.ResultsA total of 288 women were recruited (an 88% response rate) between March and May 2017. The risk formats that showed a government statement and an icon array were associated with a greater likelihood of considering SERMs relative to one that showed a novel expected frequency tree. Risk formats for raloxifene and for the high-risk vignettes were also more strongly associated with choosing to consider SERMs. No associations were found with any patient demographics.ConclusionSpecific risk formats may lead to more women considering taking SERMs to reduce breast cancer risk, especially if they are at high risk of the condition. Raloxifene may be a more acceptable SERM to patients.

Antioestrogens and breast cancer

2001 ◽  
Vol 7 (1) ◽  
pp. 21-26 ◽  
Author(s):  
S Santhanam ◽  
KJ O'Byrne
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Oestrogen Receptor ◽  
Hormonal Treatment ◽  
Beneficial Effects ◽  
Selective Oestrogen Receptor Modulators ◽  
Receptor Modulators

Antioestrogens are among the most widely used agents in the treatment of breast cancer. There has been a recent surge of interest in these compounds because of their potential breast cancer chemopreventive properties. The newer generation of antioestrogens, with increased selectivity and better toxicity profiles, have the potential to increase the effectiveness of hormonal treatment of breast cancer. The selective oestrogen receptor modulators (SERMs) hold the promise of revolutionising the care of healthy postmenopausal women with their beneficial effects on bone and lipids in addition to the chemoprevention of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document